美股A股
StockGist
Back
10-Q2026-05-14· qwen-plus

STRO · Sutro Biopharma, Inc.

0001193125-26-224170

SEC filing

Summary

Sutro reported lower revenue but meaningfully improved operating and net losses in Q1 2026, reflecting reduced operating expenses and timing-driven working capital changes — consistent with ongoing portfolio focus and cost discipline.

Key takeaways

Full analysis

Revenue

Operating and Net Losses

Operating income improved to -$29.7 million from -$68.5 million in Q1 2025 — a 56.7% improvement in magnitude of loss. Net income similarly improved to -$38.5 million from -$76.0 million, a 49.3% improvement. While both metrics remain deeply negative, the narrowing reflects meaningful reductions in operating expenses across the business. Diluted EPS was -$2.94, down from -$0.91, primarily attributable to an increase in weighted-average diluted shares outstanding — not a deterioration in underlying profitability per share basis.

Cash Flow from Operations

Liquidity and Capital Resources

Management states that, based on its current operating plan, existing capital resources are expected to fund operating expenses and capital expenditure requirements through at least the next twelve months following the filing date. This assessment aligns with disclosures characterizing Sutro’s investment objective as capital preservation to fund operations and acknowledging that significant additional financing will be required in the future to advance product candidates and meet long-term obligations. The company continues to incur significant net losses and negative cash flows from operations — a structural feature of its development-stage profile, not an indicator of near-term solvency risk.